The cornerstone of the current management of metastatic CRC includes chemotherapy and biomarker-driven therapies, notably anti-EGFR, anti-VEGF, and anti-HER2 agents, KRAS G12C inhibitors, and BRAF and MEK inhibitors, as well as ICIs and combinations thereof. Here, ERBB2 is linked to colorectal carcinoma.